Harriet Kamendi

With a strong foundation in pharmacology and toxicology, Harriet develops comprehensive preclinical testing strategies, optimizing PK/PD study designs, toxicology assessments, and safety pharmacology models to support regulatory submissions. Her expertise includes conducting gap analyses for due diligence, preparing regulatory submissions, engaging in FDA and global regulatory meetings, and overseeing nonclinical study execution to ensure compliance with evolving safety standards.

Prior to founding Kandih Bioscience, Harriet was associated with AstraZeneca as a risk assessment Senior Scientist/Study Director and Emergent BioSolutions as Manager Nonclinical Development, where she pioneered innovative toxicokinetic and safety pharmacology models that significantly reduced reliance on animal testing. She later led toxicology programs as Director of Toxicology at American Preclinical Services (currently division of NAMSA), further strengthening her expertise in CRO management and regulatory compliance.

Harriet deep knowledge of pharmacology and risk assessment, combined with hands-on industry experience, makes her a strategic partner for navigating the regulatory landscape and accelerating product development.